2010 National Summit on HIV Diagnosis, Prevention, and Access to Care, Washington DC, November 2010
1 Overcoming Obstacles to Late Presentation for HIV in Europe. N Dedes, JV Lazarus, T Coenen, A Phillips, M Weait, J Hows, D Raben, JD Lundgren, HIV in Europe Steering Committee
The 10th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010
1 Fatal and non-fatal AIDS and non-AIDS events in HIV-1 infected patients with high CD4 counts. J Reekie, J Gatell, I Yust, E Bakowska, A Rachmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft for the EuroSIDA study group.
2 Vitamin D and clinical disease progression n HIV infection: results from the EuroSIDA study. JP Viard, JC Souberbielle, O Kirk, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, A Mocroft, JD Lundgren
3 A pilot study to determine the prevalence of HIV in individuals presenting for care with selected conditions: Preliminary results: the HIV in Europe Indicator Diseases Across Europe Study. A Sönnerborg on behalf of the Indicator Diseases Across Europe Study Group.
1 Changing Antiretrovirals whilst Viral Load <50 copies/ml and Relationship with CD4 Count Changes. A Mocroft, J Reekie, C Katlama, A Lazzarin, M Ristola, H Sambatakou, J Gasiorowski, D Jevtovic, O Kirk and JD Lundgren for the EuroSIDA study group. Poster (80 KB)
2 Haemoglobin and anaemia in the SMART study. A Mocroft, AR Lifson, G Touloumi, J Neuhaus, Z Fox, A Palfreeman, M Vjecha, S Hodder, S De Wit, JD Lundgren, AN Phillips for the INSIGHT SMART study group. Poster (570 KB)
3 A Pilot Study to Determine the Prevalence of HIV in Individuals Presenting for Care with Selected Conditions: Preliminary Results: The HIV in Europe Indicator Diseases Across Europe Study. A Sönnerborg, A Mocroft, JD Lundgren, D Raben, J Gatell, A Vassilenko, V Hadziosmanovic, J Begovac, H Sørensen, M Cusini, N Clumeck, B Gazzard, J Rockstroh, M Zuin, A d'Arminio Monforte on behalf of the HIV Indicator Diseases Across Europe Study Group. Presentation (2 MB)
4 Fatal and Non-fatal AIDS and Non-AIDS Events in HIV-1 Infected Patients with High CD4 Counts According to Viral Load Strata. J Reekie, J Gatell, I Yust, E Bakowska, A Rachmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft for the EuroSIDA study group. Poster (99KB)
5 Chronic Kidney Disease in Patients with Normal eGFR at Baseline - Results from EuroSIDA. L Ryom, A Mocroft, P Reiss, B Ledergerber, S De Wit, D Duiculescu, AD Monforte, M Murphy, JD Lundgren, O Kirk for the EuroSIDA study group. Poster (99 KB)
6 Relating Protease Inhibitor Resistance at Time of Virological Failure with Drug Exposure. M Van Luin, WP Bannister, R Paredes, AN Phillip, J Bruun, J Van Lunzen, O Kirk, A d'Arminio Monforte, A Cozzi-Lepri, DM Burger, and the EuroSIDA group. Poster (80 KB)
7 Vitamin D and Clinical Disease Progression in HIV Infection: Results from the EuroSIDA Study. JP Viard, JC Souberbielle, O Kirk, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, A Mocroft, JD Lundgren for the EuroSIDA study group. Poster (98 KB)
XVIII International AIDS Conference, Vienna, July 2010
1 Causes of death in HIV/TB coinfected patients: Results from the HIV/TB collaborative study. A Panteleev, D Podlekareva, W Bannister, V Riekstina, A Rakhmanova, F Post, JM Miro, H Furrer, M Bruyand, RF Miller, E Girardi, M Losso, J Toibaro, J Caylá, N Obel, A Skrahin, N Chentsova, JD Lundgren, A Mocroft, O Kirk, and the HIV/TB study group
2 Disclosure and preceived HIV-related discrimination in Danish dental clinics. M Mansfeld, P Björkman
3 Overcoming obstacles to late presentation for HIV in Europe. JV Lazarus, D Raben, T Coenen, JD Lundgren, HIV in Europe Steering Committee
17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010
1 Rates of Cardiovascular Disease Following Smoking Cessation in Patients with HIV Infection: Results from the DAD Study. K Petoumenos, S Worm, P Reiss, S De Wit, A d'Arminio Monforte, N Friis-Moller, R Weber, P Mercie, C Pradier, J Lundgren on behalf of the DAD study group.
2 Triglycerides and the risk of myocardial infarction in the DAD study. S Worm, A Kamara, W El-Sadr, O Kirk, E Fontas, P Reiss, A Phillips, M Bruyand, A d'Arminio Monforte, M Law, R Weber, J Lundgren, C Sabin on behalf of the DAD study group.
3 Chronic kidney disease (CKD) and exposure to antiretroviral drugs (ARVs) in a large cohort with long-term follow-up: the EuroSIDA Study. O Kirk, A Mocroft, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, A Phillips, B Ledergerber, J Lundgren, for the EuroSIDA study group.Presentation Questions and answers
1 Biomarkers of inflammation and coagulation and risk of non-AIDS death in HIV/Hepatitis coinfected patients in the SMART study. L Peters, J Neuhaus, D Duprez, JD Neaton, R Tracy, MB Klein, A Mocroft, J Rockstroh, G Dore, JD Lundgren; for the INSIGHT SMART study group.
2 Predicted effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second line antiretroviral regimens in resource-limited settings. A Phillips, D Pillay, G Garnett, D Bennett, M Vitoria, V Cambiano, J Lundgren.